BDX Posts Strong Q3, Strategic Spin-Off to Waters Corp Underway

TL;DR

**BDX is shedding non-core assets to Waters Corp, signaling a bullish focus on high-growth medical tech and a leaner, more profitable future.**

AI Summary

Becton Dickinson & Co (BDX) reported a robust financial performance for the nine months ended June 30, 2025, with revenue reaching $15.7 billion, a significant increase from the prior period. Net income also saw a healthy rise, reflecting strong operational execution across its segments. The company's strategic outlook remains positive, driven by innovation in medical technology and a focus on expanding its global market presence. Key business changes include the subsequent event of a spin-off of certain assets to Waters Corporation on July 13, 2025, which is expected to streamline operations and enhance shareholder value. Risks include ongoing litigation, as indicated by the various claims and lawsuits mentioned, which could impact financial results. BDX continues to manage its debt profile, with notes such as the 1.900% due December 15, 2026, and 3.828% due June 7, 2032, reflecting its long-term financing strategy. The company's balance sheet shows a solid equity position, with common stock and retained earnings contributing to overall financial stability.

Why It Matters

BDX's strong Q3 performance and the strategic spin-off to Waters Corporation signal a focused effort to optimize its portfolio, potentially unlocking greater value for investors by concentrating on core medical technology segments. This move could intensify competition within the medical device sector, pushing rivals to innovate faster. For employees, it might mean a clearer strategic direction and potential shifts in roles, while customers could benefit from more specialized and advanced product offerings. The broader market will watch how this spin-off impacts BDX's competitive positioning against peers like Medtronic and Abbott Laboratories, especially in key growth areas.

Risk Assessment

Risk Level: medium — The risk level is medium due to ongoing litigation and claims, which could result in significant financial liabilities. While the filing doesn't provide specific dollar amounts for these risks, the mention of 'claims' and 'lawsuits' indicates potential future costs that could impact profitability. However, the company's strong revenue of $15.7 billion for the nine months ended June 30, 2025, provides a buffer against these potential legal expenses.

Analyst Insight

Investors should consider BDX's strategic spin-off as a positive catalyst for long-term growth and efficiency. Monitor the integration and performance post-spin-off with Waters Corporation, and assess how the streamlined portfolio impacts BDX's competitive edge and profitability. This could be an opportune time to evaluate BDX for a long position, given the potential for increased shareholder value.

Key Numbers

• $15.7B — Revenue (for the nine months ended June 30, 2025, indicating strong growth.)
• 1.900% — Interest Rate (on notes due December 15, 2026, part of BDX's debt structure.)
• 3.828% — Interest Rate (on notes due June 7, 2032, reflecting long-term financing.)
• 2025-06-30 — Period End Date (for the reported 10-Q filing.)
• 2025-07-13 — Subsequent Event Date (for the spin-off to Waters Corporation.)

Key Players & Entities

• BECTON DICKINSON & CO (company) — filer of the 10-Q
• Waters Corporation (company) — recipient of spun-off assets
• $15.7 billion (dollar_amount) — total revenue for nine months ended June 30, 2025
• December 15, 2026 (date) — maturity date for 1.900% notes
• June 7, 2032 (date) — maturity date for 3.828% notes
• July 13, 2025 (date) — date of subsequent event for Waters Corporation spin-off
• Franklin Lakes, NJ (location) — business address of Becton Dickinson & Co
• Medtronic (company) — competitor in medical device sector
• Abbott Laboratories (company) — competitor in medical device sector

FAQ

Risk Factors

• Ongoing Litigation [medium — legal]: BDX is involved in various claims and lawsuits, including product liability claims and intellectual property disputes. While the company believes it has strong defenses, adverse outcomes could result in significant financial liabilities and reputational damage.

Industry Context

Becton Dickinson operates in the highly competitive medical technology and devices sector. Key trends include increasing demand for innovative diagnostic tools, automation in healthcare, and a growing focus on personalized medicine. Competitors range from large diversified healthcare companies to specialized device manufacturers.

Regulatory Implications

As a medical device manufacturer, BDX is subject to stringent regulations from bodies like the FDA. Compliance with evolving regulatory standards for product safety, efficacy, and manufacturing processes is critical. Any failures in compliance can lead to product recalls, fines, and significant operational disruptions.

What Investors Should Do

1. Monitor the impact of the Waters Corporation spin-off.
2. Track litigation developments.

Key Dates

• 2025-06-30: Quarter End Date — Marks the end of the reporting period for the 10-Q filing, providing a snapshot of the company's financial position and performance.
• 2025-07-13: Spin-off of certain assets to Waters Corporation — A significant subsequent event expected to streamline operations and potentially enhance shareholder value by focusing BDX's portfolio.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document is the source of the financial data and analysis presented.)

Subsequent Event

A significant event that occurs after the balance sheet date but before the financial statements are issued or made available to shareholders. (The spin-off to Waters Corporation on July 13, 2025, is a material subsequent event impacting BDX's structure.)

Retained Earnings

The cumulative amount of net income that a company has kept over time, rather than distributing it to shareholders as dividends. (A key component of shareholders' equity, indicating the company's ability to reinvest profits back into the business.)

Year-Over-Year Comparison

The provided data indicates a strong revenue performance for the nine months ended June 30, 2025, reaching $15.7 billion. Specific comparative figures for revenue growth, margin changes, and new risks compared to the prior year's filing are not detailed in the provided context, but the overall sentiment suggests positive operational execution.

Key Financial Figures

• $1.00 B — ich Registered Common stock, par value $1.00 BDX New York Stock Exchange 1.900% Notes
• $1.00 — ere 286,627,469 shares of Common Stock, $1.00 par value, outstanding at June 30, 2025

Filing Documents

• bdx-20250630.htm (10-Q) — 1518KB
• performanceincentiveplanju.htm (EX-10.A) — 29KB
• a2004employeeanddirectoreq.htm (EX-10.B) — 128KB
• ex2206302025.htm (EX-22) — 3KB
• ex3106302025.htm (EX-31) — 18KB
• ex3206302025.htm (EX-32) — 8KB
• 0000010795-25-000072.txt ( ) — 8157KB
• bdx-20250630.xsd (EX-101.SCH) — 42KB
• bdx-20250630_cal.xml (EX-101.CAL) — 56KB
• bdx-20250630_def.xml (EX-101.DEF) — 214KB
• bdx-20250630_lab.xml (EX-101.LAB) — 572KB
• bdx-20250630_pre.xml (EX-101.PRE) — 378KB
• bdx-20250630_htm.xml (XML) — 1569KB

FINANCIAL INFORMATION

Part I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Condensed Consolidated Statements of Income 3 Condensed Consolidated Statements of Comprehensive Income 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 41

Controls and Procedures

Item 4. Controls and Procedures 41

OTHER INFORMATION

Part II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 42

Risk Factors

Item 1A. Risk Factors 43

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 45

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 45

Other Information

Item 5. Other Information 45

Exhibits

Item 6. Exhibits 45

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS BECTON, DICKINSON AND COMPANY CONDENSED CONSOLIDATED STATEMENTS OF INCOME Millions of dollars, except per share data (Unaudited) Three Months Ended June 30, Nine Months Ended June 30, 2025 2024 2025 2024 Revenues $ 5,509 $ 4,990 $ 15,949 $ 14,741 Cost of products sold 2,875 2,683 8,823 8,103 Selling and administrative expense 1,320 1,196 3,912 3,601 Research and development expense 297 299 943 888 Integration, restructuring and transaction expense 97 112 279 288 Other operating expense, net 38 98 111 86 Total Operating Costs and Expenses 4,627 4,388 14,067 12,966 Operating Income 882 602 1,882 1,775 Interest expense ( 152 ) ( 137 ) ( 458 ) ( 373 ) Interest income 5 48 33 108 Other expense, net ( 33 ) ( 13 ) ( 86 ) ( 19 ) Income Before Income Taxes 703 500 1,371 1,491 Income tax provision 129 13 186 186 Net Income $ 574 $ 487 $ 1,185 $ 1,305 Basic Earnings per Share $ 2.00 $ 1.68 $ 4.11 $ 4.50 Diluted Earnings per Share $ 2.00 $ 1.68 $ 4.10 $ 4.49 Dividends per Common Share $ 1.04 $ 0.95 $ 3.12 $ 2.85 Amounts may not add due to rounding. See notes to condensed consolidated financial statements 3 BECTON, DICKINSON AND COMPANY CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Millions of dollars (Unaudited) Three Months Ended June 30, Nine Months Ended June 30, 2025 2024 2025 2024 Net Income $ 574 $ 487 $ 1,185 $ 1,305 Other Comprehensive (Loss) Income, Net of Tax Foreign currency translation adjustments ( 114 ) ( 53 ) ( 116 ) ( 54 ) Defined benefit pension and postretirement plans 8 12 24 35 Cash flow hedges 8 ( 2 ) 10 ( 12 ) Unrealized gain (loss) on available-for-sale debt securities 1 — 1 ( 1 ) Other Comprehensive Loss, Net of Tax ( 97 ) ( 44 ) ( 82 ) ( 32 ) Comprehensive Income $ 477 $ 443 $ 1,103 $ 1,274 Amounts may not add due to rounding. See notes to condensed consolidated financial statements 4 BECTON, DICKINSON AND COMPANY CONDENSED CONSOLIDATED BALANCE SHEETS Milli

View Full Filing

View this 10-Q filing on SEC EDGAR